All In Biotech

Drug Trial Radar · NCT06466785

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 429 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

429

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

Jun 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Genexine, Inc.Industry
Sponsor type
Industry
Collaborators
PT Kalbe Genexine Biologics
First posted
Jun 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

  • Efepoetin AlfaDrug

    Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity

  • Darbepoetin AlfaDrug

    Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in hemoglobin (Hb)Time frame: Over Week 20 to Week 28

Locations

58 sites in 11 countries. Site status is shown where the registry gives one.

  • "ARABKIR" Joint Medical Center & Institute of Child and Adolescent Health

    Yerevan, Armenia · Recruiting

  • "BEST LIFE" Medical Center Armenian-Japanese Joint Venture LLC

    Yerevan, Armenia · Recruiting

  • 'Astghik'' Medical Center

    Yerevan, Armenia · Recruiting

  • Multiprofile Hospital for Active Treatment Puls AD

    Blagoevgrad, Bulgaria · Recruiting

  • Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich

    Dobrich, Bulgaria · Recruiting

  • Department of Nephrology, Dialysis Treatment, Multiprofile Hospital for Active Treatment "Dr. Tota Venkova" AD, Gabrovo

    Gabrovo, Bulgaria · Recruiting

  • First Dialysis Services Bulgaria EAD, branck Montana

    Montana, Bulgaria · Recruiting

  • Diaslys Center - Pazardzhik

    Pazardzhik, Bulgaria · Recruiting

  • Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment - Plovdiv AD, Plovdiv

    Plovdiv, Bulgaria · Recruiting

  • First Dialysis Services Bulgaria EAD, Plovdiv

    Plovdiv, Bulgaria · Recruiting

  • Department of Dialysis Treatment, University Multiprofile Hospital for Active Treatment "Medica Ruse" OOD, Ruse

    Rousse, Bulgaria · Recruiting

  • Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment "Dr. Ivan Selimski - Sliven" AD, Sliven

    Sliven, Bulgaria · Recruiting

  • Acibadem CityClinic UMHAT Tokuda EAD

    Sofia, Bulgaria · Recruiting

  • Dialysis Center - Dialmed

    Sofia, Bulgaria · Recruiting

  • Dialysis Center Hemomed EOOD

    Sofia, Bulgaria · Recruiting

  • Multiprofile Hospital for Active Treatment Sveta Anna - Varna AD

    Varna, Bulgaria · Recruiting

  • Nemocnice Cesky krumlov

    Český Krumlov, Czechia · Recruiting

  • Nemocnice Havlíčkův Brod

    Havlíčkův Brod, Czechia · Recruiting

  • HDS Privamed Healthia sro v Plzni

    Pilsen, Czechia · Recruiting

  • B. Braun Avitum s.r.o - Dialyzacni stredisko Teplice - Nefrologicka ambulance

    Teplice, Czechia · Recruiting

  • Batumi Dialysis and Nephrology Center

    Batumi, Georgia · Completed

  • Clinical Center for Nephrology Development

    Tbilisi, Georgia · Completed

  • L.Managadze National Center of Urology

    Tbilisi, Georgia · Completed

  • Tbilisi Heart And Vascular Clinic

    Tbilisi, Georgia · Completed

  • RSUP Dr. Hasan Sadikin

    Bandung, Indonesia · Completed

  • RS Islam Jakarta Cempaka Putih

    Jakarta, Indonesia · Completed

  • RSPAD Gatot Soebroto

    Jakarta, Indonesia · Completed

  • RSUPN Dr. Cipto Mangunkusumo

    Jakarta, Indonesia · Completed

  • Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia- Unità Operativa (UO) Nefrologia

    Brescia, Italy · Recruiting

  • SODc Nefrologia Dialisi Trapianto Azienda Ospedaliero Universitaria Careggi

    Florence, Italy · Recruiting

  • "Azienda Ospedaliero Universitaria ""Ospedali Riuniti"" di Foggia Unità Operativa Complessa di Nefrologia, Dialisi e Trapianto"

    Foggia, Italy · Recruiting

  • IRCCS Ospedale Policlinico San Martino

    Genova, Italy · Recruiting

  • ICS Maugeri

    Pavia, Italy · Recruiting

  • AOU Pisana UO Nefrologia Trapianti e Dialisi

    Pisa, Italy · Recruiting

  • AOU Integrata di Verona UOC Nefrologia

    Verona, Italy · Recruiting

  • Wojewodzki Szpital Specjalistyczny im. Kazimierza Dluskiego w Bialymstoku

    Bialystok, Poland · Recruiting

  • DaVita Stacja Dializ Brodnica

    Brodnica, Poland · Recruiting

  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi

    Lodz, Poland · Recruiting

  • DaVita Sp. z o.o. Pszczyna

    Pszczyna, Poland · Recruiting

  • DaVita Stacja Dializ WADOWICE

    Wadowice, Poland · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.